Table of contents
In this issue
p253 | doi:10.1038/nrd2291
Editorial: The pricing conundrum
p255 | doi:10.1038/nrd2303
News and Analysis
Price controls seen as key to Europe's drug innovation lag | PDF (432 KB)
p257 | doi:10.1038/nrd2293
New HIV drug classes on the horizon | PDF (432 KB)
p258 | doi:10.1038/nrd2294
News in Brief
Patent watch
Patent Office rejects Genentech's Cabilly claims | Purdue challenged again on OxyContin patent | Angiogenesis drugs | PDF (158 KB)
p262 | doi:10.1038/nrd2305
An Audience With
Arti Rai | PDF (106 KB)
p264 | doi:10.1038/nrd2306
From the analyst's couch
Drug developer strategies to boost competitiveness | PDF (162 KB)
p265 | doi:10.1038/nrd2296
Fresh from the Pipeline
Telbivudine | PDF (169 KB)
p267 | doi:10.1038/nrd2295
Research Highlights
Cancer: Red chillies tackle tumours | PDF (158 KB)
p269 | doi:10.1038/nrd2299
Informatics: Finding common ground | PDF (90 KB)
p270 | doi:10.1038/nrd2300
Genomics: Beyond the usual suspects | PDF (110 KB)
p270 | doi:10.1038/nrd2301
Heart disease: Unmasking molecular mechanisms | PDF (103 KB)
p271 | doi:10.1038/nrd2298
Antipsychotics: Clues in the weight-gain mystery | PDF (184 KB)
p272 | doi:10.1038/nrd2297
In brief
Computational chemistry | Anticancer drugs | HIV | Gene therapy | PDF (104 KB)
p272 | doi:10.1038/nrd2302
Perspectives
Opinion
Angiogenesis: an organizing principle for drug discovery?
Judah Folkman
p273 | doi:10.1038/nrd2115
Pathological angiogenesis plays a role in a wide range of diseases. Folkman argues that viewing angiogenesis as an 'organizing principle' in biology can lead to novel insights into the molecular mechanisms of seemingly unrelated phenomena, and facilitate the development of new therapeutic approaches.
Article series: Biomarkers
Outlook
Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers
Mark R. Trusheim, Ernst R. Berndt & Frank L. Douglas
p287 | doi:10.1038/nrd2251
The potential to use clinical biomarkers to better match therapies with specific patient populations — stratified medicine — is anticipated to have a major effect on both clinical practice and the development of new drugs and diagnostics. Trusheim, Berndt and Douglas discuss the implications of this approach to future product development strategies and market structures.
Reviews
Article series: Biomarkers
Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics
Leslie M. Shaw, Magdalena Korecka, Christopher M. Clark, Virginia M.-Y. Lee & John Q. Trojanowski
p295 | doi:10.1038/nrd2176
Biomarkers to diagnose neurodegenerative disorders early in their course and to monitor responses of patients to therapeutic interventions are urgently needed to optimize the development and application of novel disease-modifying drugs. Trojanowski and colleagues discuss progress and key issues in the discovery and validation of such biomarkers, with a focus on Alzheimer's disease.
Potential therapeutic applications of autophagy
David C. Rubinsztein, Jason E. Gestwicki, Leon O. Murphy & Daniel J. Klionsky
p304 | doi:10.1038/nrd2272
The process of autophagy has recently sparked great interest as it is recognized to be involved in a wide range of diseases. The prospect of its manipulation for therapeutic purposes has led to the discovery of many exciting new potential drug targets.
Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases
Roy Pettipher, Trevor T. Hansel & Richard Armer
p313 | doi:10.1038/nrd2266
In this Review, Pettipher and colleagues discuss antagonism of DP1 and CRTH2 prostaglandin D2 receptors as an approach to treat allergic diseases. They also review recent progress in the discovery and development of selective antagonists of these receptors.
